MAP3K5 and metabolic dysfunction-associated steatohepatitis: Moreover, the ASK1 inhibitors selonsertib and simtuzumab were recently tested in NASH clinical trials, which suggested that these compounds may reduce liver fibrosis in patients with NASH and fibrosis [94].